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1. Introduction 
Transcriptional analysis of cancer is a powerful and increasingly useful tool in biomedical 
research. Many studies are revealing transcriptional patterns using gene expression 
profiling (GEP) analyses, increasing our knowledge of cancer pathogenesis, identifying 
signatures related to prognosis and revealing the variation in responses to therapy.  
Gene-expression signatures have been identified for the most common types of non-
Hodgkin lymphomas. These studies have demonstrated the ability of these technologies to 
identify pathogenic mechanisms, new molecular targets and biological processes involved 
in lymphomagenesis (Margalit, Somech et al. 2005). Thus, in the last decade molecular 
subtypes of diffuse large B-cell, namely germinal center B-cell and activated B-cell-like 
types, have been identified, each of which has their particular prognostic and therapeutic 
implications. Likewise, GEP studies have identified relevant molecular characteristics in 
follicular lymphomas (Alizadeh, Eisen et al. 2000; Alizadeh, Ross et al. 2001), primary 
mediastinal large B-cell lymphomas (Rosenwald, Wright et al. 2003), Burkitt lymphomas 
(Dave, Fu et al. 2006; Hummel, Bentink et al. 2006) or mantle cell lymphomas (Rosenwald, 
Wright et al. 2003). Specific therapeutic targets are likely to emerge from these insights into 
the molecular pathogenesis of the different lymphomas. 
Regarding Hodgkin lymphoma (HL), GEP has provided vital clues and new insights into its 
pathogenesis (Devilard, Bertucci et al. 2002). More recently, GEP has also identified specific 
gene patterns related to tumor aggressivity and/or sensitivity to therapy (Sanchez-Aguilera, 
Montalban et al. 2006; Chetaille, Bertucci et al. 2009; Steidl, Lee et al. 2010). 
DNA microarray assays require well-preserved RNA, which is usually extracted from 
frozen tissue, so this technology is not adequate for clinical applications. However, new 
strategies for translating this information into clinical practice are currently being 
investigated, through the identification of smaller gene signatures and validation of them 
for clinical practice using simple, robust, and conventional assays such as quantitative real 
time PCR (qRT-PCR) (Sanchez-Espiridion, Sanchez-Aguilera et al. 2009; Sanchez-Espiridion, 
Montalban et al. 2010). 
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In this chapter we review recent advances in the understanding of HL biology, new data 
and improvements in the clinical management of patients in the future, from the application 
of high-throughput molecular analyses, including gene and microRNA (miRNA) 
expression, immunohistochemistry and others.  
2. Hodgkin lymphoma biology 
HL is currently classified as two distinct disease entities, nodular lymphocyte-predominant 
HL (NLPHL) and classical HL (cHL), which differ in their clinical presentation, age 
distribution and prognosis. From a biological point of view, NLPHL has been defined as a 
different disease entity, characterized by a distinct gene-expression signature similar to 
indolent B-cell non-Hodgkin lymphoma (NHL)(Brune, Tiacci et al. 2008). 
cHL represents a distinctive model of histological complexity, with a minor population of 
the characteristic Hodgkin and Reed-Sternberg (HRS) tumor cells diluted in a reactive 
inflammatory background composed of non-neoplastic B- and T-cells, macrophages, 
eosinophils, neutrophils and plasma cells. This microenvironment is very probably essential 
for HRS cell survival, as indicated by the difficulty of growing HRS cells in culture or in 
immunodeficient mice (for a review see (Herreros, Sanchez-Aguilera et al. 2008)). 
Also, HRS cells are latently infected by Epstein-Barr virus (EBV) in 40-60% of patients, 
contributing to cHL pathogenesis (Khan 2006; Kapatai and Murray 2007).   
The complex relationship between the HRS cells and their microenvironment is only 
partially understood, although important, if fragmentary, advances are being made. 
Essentially, this microenvironment represents an ineffective TH2-type immune response, in 
which a large number of chemokines and cytokines are involved (Skinnider and Mak 2002). 
HRS cells attract many cells into the lymphoma tissue, resulting in an inflammatory 
microenvironment that probably promotes the survival of HRS cells and helps them to 
escape attack from cytotoxic T or NK cells. A better understanding of these essential cellular 
interactions may inspire novel approaches for a targeted therapy of this malignancy. 
2.1 HRS cells  
The tumoral HRS cells are unique in the extent to which they have lost the characteristic B-
cell–associated gene expression pattern. Deregulation of transcription factor networks plays 
a key role in this reprogramming process. These HRS cells show strong constitutive activity 
of the NF-kappaB transcription factors. Multiple mechanisms probably contribute to this 
deregulated activation, including signaling through particular receptors and genetic lesions, 
thus identifying NF-kappaB inhibition as an interesting therapeutic approach to this 
lymphoid malignancy (Kuppers 2009). 
2.2 Hodgkin lymphoma microenvironment 
There are various lines of evidence suggesting an active role of this “microenvironment” in 
tumor biology through bidirectional signaling between the HRS and inflammatory cells that 
promotes proliferation and survival of neoplastic cells (Kuppers 2009). A complex network 
of cytokines and cell-contact-mediated interactions between tumor and inflammatory cells 
are thought to be involved and may rescue HRS cells from the proapoptotic state arising 
from their characteristic BCR deficiency by providing alternative survival signals (Figure 1). 
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Fig. 1. Chemical crosstalk between HRS cells and the microenvironment. B: B-cell; T: T-cell; 
Th2: T-helper 2-cells, MΦ: Macrophage; Eo: Eosinophil. 
This variable microenvironment gives rise to a prominent and abnormal immune reaction, 
for which reason the biology of HL can be considered unique among lymphomas. Many 
studies of HL have, therefore, focused on the cellular composition of this microenvironment, 
not only to gain more insight into the pathobiology of the disease, but also to explore 
whether these immune-related cells in some way contribute to outcome prediction. 
The tumor microenvironment is an important factor in the development and progression of 
cancer. Recent evidence suggests that cellular composition can significantly modify clinical 
outcome in hematological malignancies and particularly in follicular lymphoma and cHL 
(Dave, Wright et al. 2004; Alvaro, Lejeune et al. 2005). The exact functional role of the 
microenvironment in the pathophysiology of cHL remains a matter of debate, especially 
with regard to the role of Th2 and T-reg cells, which have a paradoxically favorable 
prognostic value (Alvaro-Naranjo, Lejeune et al. 2005; Alvaro, Lejeune et al. 2005; Kelley, 
Pohlman et al. 2007). A growing number of immunohistochemical (IHC) studies have 
attempted to evaluate the composition and prognostic significance of the various cellular 
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components, with particular interest in tumor-infiltrating lymphocytes. More recently, GEP 
studies based on DNA microarrays have demonstrated their ability to define more 
accurately the interaction pathways of HRS cells with nonmalignant reactive and stromal 
cells in cHL lymphoma tissues (see below). Therefore, a complete understanding of cHL, 
requires that both cellular components be considered.  
3. Prognostic markers: Limitations and new challenges 
3.1 The conventional international prognostic score: Current limitations 
cHL is assumed to be a curable tumor, but a substantial proportion of patients with 
advanced disease do not respond favorably to the current standard chemotherapy regimens 
based on adriamycin (Canellos, Anderson et al. 1992). Historically, outcome in cHL patients 
has been predicted using standard clinical variables such as bulk disease, patient age, 
number of nodal sites and erythrocyte sedimentation rate. The most widely used and 
reproducible prognostic score is based on clinical and analytical parameters that make up 
the International Prognostic Score (IPS). This consists of seven clinical variables, including 
serum albumin less than 4 g/dl, hemoglobin less than 10.5 g/dl, male gender, age 45 or 
above, stage IV disease, white blood cell count at least 15,000/mm3, and absolute 
lymphocyte count less than 600/mm3.  
This clinical measure, although widely accepted, still does not accurately identify, at 
diagnosis, a significant fraction of patients with very poor prognosis (Gobbi, Zinzani et al. 
2001) and it´s not applicable to patients with early-stage HL (Hasenclever and Diehl 1998).  
Additionally,  other study noted that the IPS score had no significant prognostic influence in 
modern series of patients and that only age and stage IV disease remained significant in 
multivariate analyses (Sanchez-Espiridion, Montalban et al. 2010). A re-evaluation of the 
IPS, together with the identification of new biological prognostic factors in larger 
populations of patients, is necessary to improve patients stratification into clearly defined 
risk groups for which risk-adapted therapeutic strategies are suitable. 
3.2 Risk stratification and new approaches to clinical guidance: Biological prognostic 
factors and markers in cHL 
HL is generally a curable tumor; so, research currently focuses on identifying patients with a 
low probability of cure who might benefit from more novel and/or intensive treatment 
strategies, and those with a better prognosis who are suitable for less toxic therapies. To 
establish a more rational risk-adapted treatment strategy the identification of truly high-risk 
populations requires supplementation with molecular markers. In this context, biological 
factors may serve as prognostic markers and provide novel targets for cHL therapy. 
Moreover, the addition of biological markers to the already recognized clinical prognostic 
factors (including those of the IPS) may improve patient risk stratification. 
This chapter summarizes new insights into cHL biology in a clinical context and the role 
that new technologies have played in identifying biological markers with future prognostic 
and therapeutic applications. 
Many markers have recently been identified as prognostic factors in HL, including surface 
receptors, intracellular proteins, cytokines, and genetic abnormalities (amplifications, 
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deletions, epigenetic silencing), or alterations in miRNA in HRS cells and surrounding 
inflammatory cells. Technical advances such as microarray-based gene and miRNA 
expression profiling, RT-PCR platforms, comparative genomic hybridization (CGH), SNP 
arrays, microdissection and IHC studies have led to new discoveries (see below). Their 
integration with the classical parameters will further improve the understanding of the 
disease and the management of patients.  
Gene expression profiling studies in cHL  
It has been difficult to identify biological markers for several reasons, including the scarcity of 
large and confirmatory prospective trials, the lack of reproducibility and feasibility of assays 
and the negligible improvement upon already used clinical risk factors (IPS or others). The 
characteristic histological heterogeneity and scarcity of tumoral cells have also hindered 
molecular studies in HL. However, several studies have analyzed GEP in whole tissue sections 
and identified specific transcriptional patterns in the tumoral cells and the non-tumoral 
microenvironment. Additionally, other studies in HL have demonstrated differential gene 
expression patterns between HRS cells and normal mature B-cells, providing vital clues for 
understanding the pathogenesis of the disease (Kuppers, Klein et al. 2003).   
DNA microarrays are currently the best developed and most widely used high-throughput 
molecular technique for identifying biological markers that rely on array-based gene 
expression analyses using whole-tissue sections. IHC staining has been used as a validation 
tool, but the technique has inherent limitations, such as the poor reproducibility of the 
results generated.  
Gene expression studies in cHL initially focused on elucidating HRS cell-specific genes and 
the biological mechanisms underlying cHL pathogenesis (Kuppers, Klein et al. 2003). 
Subsequently, the relationship between cell microenvironment and HRS cells with clinical 
outcome was investigated (Devilard, Bertucci et al. 2002; Sanchez-Aguilera, Montalban et al. 
2006; Chetaille, Bertucci et al. 2009) (Table 1). These studies reported prognostic signatures 
related to tumor HRS and microenvironment cells, identifying genes that, although not 
completely overlapping, did suggest the involvement of the same cellular subpopulations 
(macrophages, B-cells, T-cells) as those affecting clinical outcome (for a recent review 
(Bertucci, Chetaille et al. 2011)).  
The first study to suggest the existence of correlations between gene expression profiles, 
mainly microenvironment-related genes, and prognosis was that of Devilard et al. 
(Devilard, Bertucci et al. 2002). They measured the mRNA expression levels of around 1,000 
genes in 34 benign and malignant lymphoid samples including 21 cHL tissue samples and 
identified three molecular groups of HL. Samples from patients with bad outcomes 
clustered together, whereas the two other groups contained most of the good outcome cases. 
These good outcome cases overexpressed genes involved in apoptosis induction and cell 
signaling (including cytokines), while the bad outcome samples were characterized by 
upregulation of genes involved in fibroblast activation, angiogenesis, extracellular matrix 
remodeling, cell proliferation and downregulation of tumor suppressor genes. However, the 
number of genes and samples analyzed was small, thus preventing any robust conclusions 
being drawn. 
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Reference 
cHL tumor 
samples 
Microarray 
platform Nº 
of genes 
Control 
samples 
Gene 
signature 
associated 
with 
Validation 
set 
Multivariate 
analysis 
Devilard, 
Bertucci et 
al. 2002 
21 samples 
limited and 
advanced 
stages 
~1000 genes 
Cell lines 
Tissues 
(adenitis, 
lymphomas) 
Sustained 
CR 
No No 
Sanchez-
Aguilera, 
Montalban 
et al. 2006 
29 samples 
advanced 
stages 
~9.348 genes Cell lines 
Sustained 
CR 
250 samples 
IHC TMA 
No 
Chetaille, 
Bertucci et 
al. 2009 
63 samples 
limited and 
advanced 
stages 
~16.000 
genes 
Cell lines 
Tissues 
(adenitis, 
lymphomas) 
Sustained 
CR 
146 samples 
IHC TMA 
EFS OS 
Steidl, Lee 
et al. 2010 
130 samples 
limited and 
advanced 
stages 
~25.000 
genes 
No 
Absence of 
P 
166 samples 
IHC TMA 
PFS OS 
cHL: classical Hodgkin lymphoma; RS: Reed Sternberg, IHC: immunohistochemistry; TMA: Tissue 
microarray; EFS; event-free survival; CR: complete remission;  P: progression; OS: Overall survival; PFS: 
progression-free survival, DSS: disease-specific survival 
Table 1. Gene expression profiling studies in cHL. 
A second important study was published by our group (Sanchez-Aguilera, Montalban et al. 
2006), which used gene expression analysis to identify specific gene signatures associated with 
favorable or unfavorable clinical outcomes. We identified a 145-gene signature related to poor 
treatment response. These genes were grouped into four clusters representing genes expressed 
either by the tumor cells (regulation of mitosis and cell growth/apoptosis) or the tumor 
microenvironment. Thus, some genes reflect cell populations that participate in previously 
reported immune responses (ten Berge, Oudejans et al. 2001; Alvaro, Lejeune et al. 2005), 
including those expressed by T-cells (CD8B1, CD3D, CD26, SH2D1A), macrophages 
(ALDH1A1, LYZ, STAT1) and plasmacytoid dendritic cells (ITM2A). Other genes are involved 
in extracellular matrix adhesion and remodeling of the extracellular matrix (TIMP4, SPON1, 
LAMB1). Genes involved in fibroblast function and chemotaxis, and molecules expressed 
either by antigen-presenting cells (CR1, HLA-DR3) or specific populations of B-cells (IRTA2, 
VDR) were also identified in this research. This study was the first to present evidence of the 
important role of tumor-associated macrophages within a prognostic context in HL. The other 
half of the genes identified were mainly expressed by the HRS cells and are involved in 
apoptosis regulation (CYCS, CASP14, HSPA1L), signal transduction (PDCD10, PRKACB), 
metabolism and cell growth (COX7A2, MYCN, DCK) and in the regulation of the mitotic 
checkpoint (MAD2L1, BUB1, STK6, CDC2, CHEK1, TOP2A). Additionally, the link with 
survival was validated for eight genes (ALDH1A1, STAT1, SH2D1A1, TOP2A, RRM2, PCNA, 
MAD2L1, CDC2) by IHC in an independent set of 235 samples. Finally, alterations in the 
regulation of the mitotic checkpoint in HRS cells were also validated.  
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In another study, Chetaille et al. (Chetaille, Bertucci et al. 2009) analyzed gene expression 
data from a set of 63 cHL tissue samples with both early and advanced stages, including 
control tissues (lymphadenitis) and cHL cell lines and cHL samples from patients. Available 
clinical data allowed the comparison of profiles from 41 cases with favorable outcome and 
21 with unfavorable outcome, identifying a set of 450 genes associated with survival. The 
authors found that expression of genes associated with B-cells and apoptosis was associated 
with good prognosis, whereas genes involved in stroma remodeling were correlated with 
poor prognosis. An independent set of 146 samples was analyzed by IHC, enabling the 
prognostic significance of some of the identified markers including FOXP3, CD20 and 
TOP2A to be validated. These proved to have a remarkably strong prognostic value for 
BCL11A in the series. Additionally, a gene signature associated with the EBV status of 
samples was identified. This seems to be characteristic of the Th1 antiviral immune 
response, thus providing new clues about the differences between EBV+ and EBV– cases. 
The influence of EBV infections on HL and the knowledge obtained from GEP is discussed 
in more detail below. 
Finally, a study performed by Steidl et al. (Steidl, Lee et al. 2010)  reported the results of a 
retrospective study using IHC and GEP. Initial analyses of RNA isolated from 130 frozen 
specimens identified a GEP significantly associated with primary treatment failure that 
included increased gene signatures related to tumor-infiltrating macrophages, angiogenic 
cells, adipocytes, HRS cells, with overexpression of matrix metallopeptidases (like MMP1) 
and underexpression of gene signatures related to germinal center B-cells. A validation 
study using IHC showed that low percentages of CD68+ macrophages (< 5 percent) 
correlated with higher progression-free survival (PFS), with a 100 percent disease-specific 
survival (DSS) rate observed for patients with limited-stage disease (stages IA and IIA) and 
absence of tumor-infiltrating macrophages.  
These data are consistent with a previous observation made by Chetaille et al. (Chetaille, 
Bertucci et al. 2009), which showed reduced presence of background small B-cells (≤ 10 
percent) and overexpression of MMP1 associated with shorter survival. Interestingly, in 
multivariate analyses, CD68+ macrophages remained an independent adverse prognostic 
factor for DSS, outperforming the IPS. 
RT-PCR models 
It is now feasible to apply multigenic predictive molecular tests in a routine setting by using 
alternative techniques, like quantitative RT-PCR. An assay for patients with advanced cHL 
has recently been described that incorporates a limited number of genes and pathways from 
both tumor and microenvironment cell components, designed for routine formalin-fixed 
paraffin-embedded (FFPE) samples (Sanchez-Espiridion, Montalban et al. 2010). Thirty 
genes were chosen on the basis of the findings of two previous studies (Sanchez-Aguilera, 
Montalban et al. 2006; Sanchez-Espiridion, Sanchez-Aguilera et al. 2009) and their 
deployment in 282 FFPE samples enabled a prognostic model to be developed. The model 
included 11 genes from four functional pathways (apoptosis, cell cycle regulation, 
macrophage activation and interferon regulatory factor-IRF4). This 4-cluster/11-gene 
signature was included in a final algorithm (defined as molecular risk score, MRS) that was 
able to identify subgroups of patients with different probabilities of treatment failure.   
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One of the well established clinical variables (stage IV) was also included in the score, thus 
combining the main molecular characteristics of the treatment response-related tumors and 
tumor burden estimates into a single scoring system. The multivariate Cox model indicated 
that most patients with stage IV cHL and with a high MRS (≥ 0.3) will have a very poor 
outcome, with a 5-year FFS probability of 24.3 percent and overall survival (OS) probability 
of 76.3 percent (Sanchez-Espiridion, Montalban et al. 2010). This assay represented another 
interesting, although preliminary, attempt to translate gene profiling results into routine 
practice, providing a tool for further exploring and refining the already available biological 
and clinical prognostic markers. 
 
Reference Technique HRS cells signatures 
Microenvironmental 
signatures 
Sanchez-Aguilera, 
Montalban et al. 2006 
GEP 
Cell cycle, apoptosis, 
signals transduction 
Immune response, 
extracellular matrix, 
adhesion and cell-cell 
signaling 
Chetaille, Bertucci et 
al. 2009 
GEP 
BCR signaling,  apoptosis, 
cell metabolism 
Stroma remodeling genes 
Sanchez-Espiridion, 
Sanchez-Aguilera et al. 
2009 
RT-PCR array 
Cell cycle (G2-M and G1 
pathway), histones, 
chaperones and MAP 
kinase pathway 
T-cell pathway, 
monocyte, macrophage 
Sanchez-Espiridion, 
Montalban et al. 2010 
RT-PCR array Cell cycle, apoptosis 
Macrophage activation, 
IRF4 
Steidl, Lee et al. 2010 GEP HRS cell-related genes 
Macrophages, monocytes , 
metalloproteinases, 
angiogenic cells 
GEP: gene expression profiling; RT-PCR: reverse-transcription polymerase chain reaction 
Table 2. Gene expression signatures outcome related in cHL.   
Comparative genomic hybridization (CGH) and SNP array studies  
Several studies have assessed the association between SNPs and the risks of developing 
HL. One of these compared 200 HL cases and 220 controls to examine the relationship 
between genetic polymorphisms in cytokine genes and the susceptibility to developing 
HL (Monroy, Cortes et al. 2011). It describes a set of four genes (COX2, IL18, ILR4, IL10) 
out of 38 that are correlated with an increased risk of developing cHL. Once more, this 
highlights the importance of aberrant cytokine signaling in HL pathogenesis. The authors 
also showed that genetic variants in DNA repair genes are significantly associated with 
the risk of developing cHL  
Array CGH (aCGH) studies showed genomic imbalances in cHL cases affecting several 
genes belonging to the main cell-survival pathways known to be activated in HL (JAK/ 
STAT, NF-KB, API-Jun-B). However, the correlation between these genes and clinical 
outcomes was not calculated. A recent study by Steidl et al. (Steidl, Telenius et al. 2010) 
reported copy number gains on chromosome 16p as being less frequent in patients with 
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primary refractory disease and strongly associated with prognosis after ABVD 
chemotherapy. These results could be related to the presence of the multidrug resistant gene 
ABCC1 located in this chromosomal region (16p13.11). In addition, frequent losses on 4q27 
(IL2/IL21 genes) and 17p12, and gains on 19q13.3 (BCL3/RELB) have also been described as 
being associated with ABVD resistance (Slovak, Bedell et al. 2011).  
Immunohistochemical markers and gene expression studies  
Some of the markers identified by GEP have been identified as being of potential use, 
leading to their clinical application by IHC techniques, especially those associated with the 
complex reactive inflammatory infiltrate.  
BCL2. The relationship between BCL2 expression and patient outcome in HL is a controversial 
issue with studies reporting BCL2 expression to be independently associated with reduced FFS 
in addition to other clinical prognostic variables (age over 45 years, stage IV disease, low 
albumin and elevated lactate dehydrogenase) (Rassidakis, Medeiros et al. 2002), whereas 
others have not demonstrated the same relationship (Montalban, Garcia et al. 2004). 
p21 and p53. Similarly to BCL2, other markers like p21 and p53 have been associated with 
treatment outcomes (Sup, Alemany et al. 2005). 
MMP11 is a marker of matrix metallopeptidases expressed by tumor-associated 
macrophages, found to be associated with treatment failure by GEP and IHC (Steidl, Lee et 
al. 2010) with good discriminatory power with respect to patient outcome. More than 1% 
MMP11 staining by IHC predicted reduced PFS survival in both univariate and multivariate 
analyses.  
CD20 encodes a B-lymphocyte cell-surface antigen and has been evaluated by IHC in several 
studies (Chetaille, Bertucci et al. 2009; Steidl, Lee et al. 2010), which revealed a positive 
association of an increased number of tumor-infiltrating CD20+ cells with both prolonged 
PFS and DFS. Similar findings, in which high numbers of CD20+ cells present in the 
inflammatory background were correlated with improved event-free survival (EFS) and OS 
were reported by Chetaille (Chetaille, Bertucci et al. 2009). No correlation with the number 
of CD20+ HRS cells and patient outcome was found in Steidl’s study (Steidl, Lee et al. 2010) 
or another one of 598 patients (Rassidakis, Medeiros et al. 2002). However, a small study 
performed by Portlock et al. (Portlock, Donnelly et al. 2004) in a set of 248 samples showed 
that both time to treatment and OS were significantly lower in patients treated with ABVD 
with CD20+ cells.   
Tzankov et al. found that the presence of more than 10 percent of CD20+ HRS cells was 
associated with worse patient outcomes in patients treated from 1974 to 1980 whereas there 
was no effect on FFS in patients treated from 1981 to 1999 (Tzankov, Krugmann et al. 2003). 
Thus, the prognostic relevance of CD20 in HL might depend on other factors, such as the 
therapeutic modality and the criteria used to define CD20 positivity. As is the case with 
many other identified markers, these results need further validation in prospective studies 
to determine their reproducibility. 
CD68 is a macrophage marker encoding a transmembrane glycoprotein that is strongly 
expressed by human monocytes and tissue macrophages. It is a member of the 
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lysosomal/endosomal-associated membrane glycoprotein (LAMP) family. In the 
aforementioned study (Sinha, Adhikari et al. 2001) the initial finding of a tumor infiltrating 
macrophage gene signature associated with treatment failure prompted an additional IHC 
validation of CD68 expression relation with clinical outcome. In univariate analysis, the 
presence of a large number of infiltrating CD68+ cells was correlated with reduced PFS and 
DFS. Remarkably, this marker is better than the IPS in predicting DFS in multivariate analysis 
(p=0.003 vs. p=0.030) and as such is currently a matter under further investigation in many 
studies that are attempting to validate its predictive value (Kamper, Bendix et al. 2011). 
Similar findings correlating the presence of tumor-infiltrating macrophages with adverse 
patient outcomes have also been  described in follicular lymphoma (Dave, Wright et al. 
2004; Farinha, Masoudi et al. 2005), suggesting that interactions between the malignant 
lymphoma cells and the microenvironment are critical to the pathogenesis and progression 
of these diseases.  
Despite these results, the use of CD68 alone as a marker is currently a matter of interest, 
with several studies having produced contradictory results (Azambuja, Natkunam et al. 
2011). Nevertheless, there is no doubt about their prognostic value in cHL.  
CD163 is a monocyte/macrophage-specific protein in the scavenger receptor cysteine-rich 
superfamily that appears to be involved in anti-inflammatory functions believed to be 
predominantly associated with M2 (macrophages). This marker has been found to be 
correlated with outcome in several studies in a similar manner to CD68 (Steidl, Lee et al. 
2010; Kamper, Bendix et al. 2011). However, it is considered to be more specific and thus 
more accurate for macrophage identification than CD68.  
T-cells. The presence of T-cells in the inflammatory infiltrate also seems to influence patient 
outcomes and several studies have examined the ratio of regulatory T-cells (CD4+, CD25+ 
and FOXP3 expression) and cytotoxic T-cells (TIA-1+ or granzyme B expression) in 
relationship to OS and DFS rates (Alvaro, Lejeune et al. 2005). The ratio of regulatory 
FOXP3+ T-cells to cytotoxic T/NK (natural killer cells) with granzyme B expression 
independently predicts patient survival.  
Other markers. A variety of other prognostic markers have been described in HL. Increased 
serum levels of soluble CD30 (Zanotti, Trolese et al. 2002), IL-10, BAFF, TNFα, TARC and 
VEGF have all been associated with adverse patient outcomes (Casasnovas, Mounier et al. 
2007). In several studies, combining the CD30 level with the IPS gave improved predictive 
values (Ma, Ding et al. 2009; Renna, Mocciaro et al. 2009). 
3.3 Influence of EBV  
Finally, it is essential to mention studies concerning the role of EBV infection in cHL. Before 
the use of GEP by DNA arrays, only a few differences had been found between the EBV + 
and EBV- microenvironments, and these had not been comprehensively characterized.  
GEP studies looking for EBV-induced alterations showed that Epstein-Barr nuclear antigen 
1 (EBNA1) upregulated the expression of a chemokine (CCL20) in EBV+ cHL cells, 
ultimately leading to increased chemotaxis of T-regulatory cells (Baumforth, Birgersdotter et 
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al. 2008). Additionally, Chetaille et al. (Chetaille, Bertucci et al. 2009) demonstrated that 
EBV+ and EBV- cHL cases can be clearly separated from each other by a robust gene 
signature involving innate immunity and antiviral responses in EBV+ cases. Thus, EBV+ 
cases overexpressed antiviral genes such as NS1BP, PLSCR1 and OAS, together with TLR8 
receptor and MDA5 helicase, which are both, involved in the recognition of viruses and 
mediate innate immunity against viral infection. The molecular profile of EBV+ tumors 
(overexpression of IFNG, CXCL9, CXL10, and CXCL11/ITAC) also provided evidence of 
intratumoral Th1 activity in EBV+ cHL cases, which might be orchestrated by IFNG. 
Nonetheless, EBV+ patients did not have a better outcome, suggesting that the intratumoral 
immune reaction described is inadequate for eliminating tumor cells.  
ITK (IL-2–inducible T-cell kinase) deficiency, a novel primary immunodeficiency disease 
characterized by severe EBV associated immune dysregulation commonly progresses to 
cHL with a variable treatment response (Rezaei, Hedayat et al. 2011). Additionally, three 
cases EBV-positive HL associated to this deficiency were subsequently found to harbor a 
homozygous nonsense mutation in the ITK gene (Stepensky, Weintraub et al. 2011). 
Additionally, the study of Steidl et al. (Steidl, Lee et al. 2010) showed that CD68 and CD163 
markers were both associated with latent EBV infection of the malignant cells, thus 
highlighting the potential prognostic implications of EBV infection. Despite these results, the 
impact of EBV infection on clinical outcome remains unclear; more studies are needed to 
elucidate its exact role in cHL patients.  
4. miRNAs: A new approach to elucidating the biology of Hodgkin’s 
lymphoma  
Several studies have demonstrated the role of miRNA deregulation in cancer pathogenesis 
and treatment response in several tumor models. Others confirm that miRNAs are good 
biomarkers for cancer diagnosis and prognosis, including hematological malignancies. 
miRNAs are small, noncoding RNAs that regulate the expression of multiple mRNAs by 
binding to the 3’ untranslated region (UTR) of their target genes. miRNAs are the best 
characterized members of a family of noncoding RNAs (ncRNAs) that are now the object of 
intense investigation. They function by targeting mRNA and inducing its degradation or 
inhibiting its translation. A number of studies suggest that miRNAs may regulate around 
30% of the genome. As a consequence they are implicated in almost every cellular process, 
and, in fact miRNA expression has been shown to be tissue-specific, playing key roles in the 
control of the various biological processes such as differentiation, proliferation and others, 
all of which are involved in cancer pathogenesis. The deregulated expression of miRNA in 
tumoral samples compared with their normal counterparts, and their frequent genomic 
location in fragile chromosomal sites, also points to their role in the development of cancer. 
In fact, specific miRNA signatures have been identified for some tumor types, and they are 
thought to have tumor suppressor or oncogenic properties (for which reason they are 
termed “oncomirs”), as well as metastasis regulatory functions. miRNAs are encoded by 
intronic or intergenic regions. They are first transcribed to pri-miRNA, then processed to 
pre-miRNA by the Drosha complex, and subsequently exported to the cytoplasm, where the 
RNase Dicer cleavages them to generate a double strand molecule of 21-25 nucleotides. One 
of the two chains is then joined to the RNA-induced silencing complex (RISC), which 
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interacts with Argonaute proteins and binds to 3’UTR on target mRNAs, inducing their 
degradation and/or blocking translation (Esquela-Kerscher and Slack 2006). 
Altered miRNA expression has a role in hematopoietic malignancies. One of the first pieces 
of evidence of the role of miRNAs in cancer came from a study of B-cell chronic lymphocytic 
leukemia where miR-15 and miR-16 were downregulated due to hemi- or homozygous 
chromosomal deletion at 13q14 (Calin, Dumitru et al. 2002). As mentioned before, several 
miRNA loci reside on chromosomal fragile sites, which are frequently altered in cancer. 
These include the miR-15a/16 cluster, which is also deleted in pituitary adenomas, miR-143 
and miR-145, which are located in the 5q33 that is deleted in lung cancer (Calin and Croce 
2006), and the miR-17-92 cluster, which is frequently amplified in B-cell lymphomas (Ota, 
Tagawa et al. 2004; He, Thomson et al. 2005) and lung cancers (Hayashita, Osada et al. 2005). 
Expression of specific miRNAs is implicated in B-cell and hematological differentiation, and 
regulates germinal center formation (Kluiver, Kroesen et al. 2006; Thai, Calado et al. 2007; 
Zhou, Wang et al. 2007). It is possible that miRNA losses and gains have a significant role in 
MCL by regulating CCND1 mRNA expression (Chen, Bemis et al. 2008). Another study in 
MCL showed that the most essential pathways and genes in MCL pathogenesis are 
potentially targeted simultaneously by multiple miRNAs, suggesting that transcriptional 
regulation by miRNAs in MCL is the result of the concurrent deregulation of multiple 
miRNAs with related targets (Di Lisio, Gomez-Lopez et al. 2010).  
Furthermore, they may constitute markers of differentiation stage, malignant 
transformation, sensitivity or resistance to specific drugs. Their capacity as prognostic 
markers has also been demonstrated in lymphomas. Montes-Moreno et al. have developed a 
model based on miRNA expression, valid for FFPE samples, that uses RT-PCR to predict OS 
and PFS in chemoimmunotherapy-treated DLBCL patients, improving the prediction just 
based on clinical variables (Montes-Moreno, Martinez et al. 2011).  
Some attempts have been made to elucidate specific miRNA signatures for the characteristic 
HRS cells and their microenvironment. Preliminary work showed that miRNA losses and 
gains may explain some of the biological and clinical features of different lymphoma types, 
and recent analyses of miRNA expression in cHL-derived cell-lines and tumors have also 
demonstrated deregulated expression of some miRNAs in this malignancy. Overexpression 
of BIC/miR-155 has been found in cHL cell lines and samples by qRT-PCR analysis 
(Kluiver, Poppema et al. 2005) but not in other NHL types, except some PMBL and DLBCL 
samples. miRNA profiling of cHL-derived cell lines performed with qRT-PCR and 
microarrays has revealed specifically expressed miRNAs that include miR-17-92 cluster 
members, miR-16, miR-21, miR-24 and miR-155  (Gibcus, Tan et al. 2009) and a significant 
downregulation of miR-150 in cHL. The authors also demonstrated the targeting of IKBKE 
by miR-155, among others, in cHL cell lines; thus, miR-155 expression in HL might represent 
an attempt to reduce NFkappaB activity in this lymphoma. In primary tumors, comparison 
of miRNA profiles of microdissected HRS cells from cHL patients, four common cell lines 
(HDLM2, L540, KMH2 and L1236) and CD77+ germinal center B-cells (used as normal 
counterparts) yielded a distinct cHL signature of 12 overexpressed and three 
underexpressed miRNAs (Van Vlierberghe, De Weer et al. 2009) including some of the 
previously described miRNAs, including miR-21 and miR-155. Additionally, a 25-specific 
miRNA signature differentiating cHL and reactive lymphoid nodes was presented by 
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Navarro et al. (Navarro, Gaya et al. 2008). When studying cell lines, some of the miRNAs in 
the samples and cell lines were found to be different, suggesting that this could be due to 
the microenvironment or to the immortalization process of the cell lines. They also identified 
some miRNAs (miR-96, miR-128a, miR-128b) whose expression was related to the presence 
of EBV, although no prognostic implication of the identified specific EBV-related miRNAs 
was demonstrated.  
These results imply that a small subset of miRNAs may define tumor entities better than 
microarray expression data from thousands of messenger RNAs, and suggest that miRNAs 
may play an important role in the biology of cHL, and may be useful in the development of 
therapies targeting miRNAs in tumor cells.  
Although cHL-specific miRNA signatures have been proposed, their potential prognostic 
role remains unclear. There are few observations that link miRNA deregulation and clinical 
characteristics of the patients. Overexpression of miR-328 has been found in advanced cHL 
stages (III-IV stages) (Navarro, Gaya et al. 2008), and lower miR-138 levels. However, the 
potential prognostic role of miRNA signatures in cHL has not yet been sufficiently well 
investigated in larger series of patients. 
Taken together, these findings suggest that miRNAs may play significant roles in HL 
pathogenesis, and could help to explain its biology, being additionally useful for patient risk 
stratification and development of new therapeutic approaches. Thus, the relevance of 
miRNA expression in cHL and its putative value for outcome prediction is worthy of further 
investigation. 
Recently, our group has identified specific profiles from tumor cells and their non-tumoral 
microenvironment by miRNA expression studies. Initial analyses suggest that clinical 
outcome can be predicted by models that integrate miRNA signatures. These preliminary 
findings suggest a possible role for miR-21 and miR-30d as potential targets to overcome 
treatment resistance in cHL (Sánchez-Espiridión B, Figueroa V et al. 2011). 
5. Perspectives  
An increasing body of knowledge in cHL pathogenesis, and the complex relationship 
between the tumoral HRS cells and the microenvironment has been built up from gene and 
miRNA profiling studies. The correlations that these studies identify, spotlighting tumor-
infiltrating macrophages in classic HL, reinforce the critical roles of microenvironmental and 
immunomodulatory interactions between RS and non-tumor cells, stromal, cytokine, and 
membrane molecules in disease pathobiology and treatment responsiveness. As we have 
seen in this chapter, these studies have led to remarkable discoveries such as the relevance 
of B-cells and macrophages in patient outcome, and to the identification of several new 
prognostic markers. All these results, including the optimization of new technologies such 
as RT-PCR in FFPE tissues and miRNA profiling, are clinically promising. However, further 
validation in large and independent series of patients is needed for them to be included as 
part of clinical routine. There is no doubt that their integration with results generated by 
other modern high-throughput molecular analyses (such as proteomics) will further 
improve our understanding of the disease and the patient management. 
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